Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Vij Discusses the Potential of Quadruplets in Myeloma

November 3rd 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the potential of quadruplets in the treatment of patients with multiple myeloma.

Dr. Smith Discusses CAR T Cell Persistence in Myeloma

November 2nd 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Expert Explains Latest Developments in Multiple Myeloma

November 1st 2018

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Daratumumab Plus Lenalidomide/Dexamethasone Improves PFS in Frontline Myeloma Trial

October 30th 2018

Adding daratumumab to lenalidomide and dexamethasone reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Dr. Fakhri on Daratumumab Plus VMP in Multiple Myeloma

October 30th 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.

Dr. Martin on Transplant and Maintenance for Patients With High-Risk Myeloma

October 30th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses transplant and maintenance for the treatment of patients with high-risk multiple myeloma.

Dr. Schroeder on Tolerability of Treatment For Myeloma

October 25th 2018

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Dr. Vij on the Optimal Induction Therapy in Multiple Myeloma

October 20th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Dr. Fakhri on the Use of Carfilzomib in Multiple Myeloma

October 16th 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Dr. Martin on Autologous Stem Cell Transplant in Multiple Myeloma

October 12th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Emerging Agents Offer Hope in Late Relapse Myeloma

October 11th 2018

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

Dr. Valent on MRD Negativity in Multiple Myeloma

October 11th 2018

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

October 10th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Individualized Regimens Instrumental After Early Relapse in Myeloma

October 9th 2018

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

High-Dose Chemotherapy and ASCT Reign Supreme in Frontline Myeloma

October 8th 2018

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

FDA Grants Selinexor Priority Review for Multiple Myeloma

October 7th 2018

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Expert Discusses Transplant and Emerging Strategies in Myeloma

October 5th 2018

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Frontline Options Evolving in Newly Diagnosed Myeloma

October 5th 2018

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

Dr. Green on Early Relapse in Multiple Myeloma

October 4th 2018

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

NGS Assay for MRD Detection Gains FDA Approval for 2 Blood Cancers

October 3rd 2018

The FDA has approved the next-generation sequencing assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia or multiple myeloma.